A recently published systematic review and meta-analysis suggests that acetyl-L-carnitine (ALC) may have a meaningful role to play for people with depression, especially treatment-resistant or late-life depression.
The findings do not establish ALC as a replacement for antidepressants or psychotherapy; however, they add to growing evidence that depression may involve more than neurotransmitter imbalance alone. Mitochondrial function, brain plasticity, inflammation and metabolic health may also influence who develops depression—and who responds to treatment.
ALC—Depression Biomarker and Treatment
Acetyl-L-carnitine, produced naturally in the body, helps transport fatty acids into mitochondria, structures that generate energy inside cells. Because the brain has high energy demands, disruptions in mitochondrial function may affect mood, cognition and resilience to stress.
ALC crosses the blood-brain barrier more efficiently than standard L-carnitine, which explains the compound’s increased attention in psychiatric research, where investigators are exploring its possible effects on neuroplasticity, neurotransmission and cellular energy production.
Previous research has suggested that people with major depressive disorder may have lower ALC levels than individuals without depression. Lower levels of ALC have also been associated with greater depression severity and longer illness duration. These observations raise an intriguing possibility—ALC may be both a potential biomarker and a treatment target.
What Did the New Study Examine?
Published in Neuropsychiatric Disease and Treatment (link to full text below), the review by Kumar and colleagues synthesized evidence from 15 clinical studies. Fourteen were randomized controlled trials and one was an open-label study. Together, the studies included 809 participants, although only 10 trials had sufficient data to be included in the main meta-analysis.
Participants received ALC either alone or alongside another treatment. The studies included people with major depressive disorder, dysthymic disorder and bipolar depression. Treatment periods ranged from approximately 40 days to 12 weeks, with reported ALC doses ranging from 1 to 3 grams per day.
The researchers compared changes in depressive symptoms using common clinical rating scales, including the Hamilton Depression Rating Scale, Beck Depression Inventory and Montgomery–Åsberg Depression Rating Scale.
Depressive Symptoms Improved More with ALC Overall
Across 10 randomized controlled trials involving 725 participants, the pooled results favored ALC over control conditions. The primary analysis found a statistically significant reduction in depressive symptoms, with a standardized mean difference of −1.20.
The strongest evidence appeared on the Hamilton Depression Rating Scale—in that analysis, ALC was associated with greater symptom improvement than the control treatment. Results using the Beck Depression Inventory and MADRS also favored ALC, although their confidence intervals included the possibility of no clear difference.
That distinction matters. The overall direction of results was encouraging, but the findings were not equally conclusive across every measurement tool.
The review also found that ALC performed similarly to standard antidepressant medications in the limited head-to-head studies available. In trials comparing ALC with amisulpride or fluoxetine, symptom improvement was broadly comparable. ALC appeared to be better tolerated in some of these comparisons, although the number of studies was small.
Previous research has suggested that people with major depressive disorder may have lower ALC levels than individuals without depression. These observations raise an intriguing possibility—ALC may be both a potential biomarker and a treatment target.
Older Adults May Be Especially Responsive
One of the most notable findings came from the age-based subgroup analysis. Trials involving adults aged 60 and older showed a larger apparent benefit than studies primarily enrolling younger adults.
In older-adult studies, the pooled standardized mean difference was −1.88, compared with −0.28 in studies involving younger participants. The researchers caution that this finding should be interpreted carefully because the number of trials in each subgroup was limited.
Still, the result is biologically plausible. Late-life depression may involve mitochondrial dysfunction, inflammation, vascular changes, cognitive impairment and neurodegenerative processes. A treatment that supports cellular energy metabolism and neuroplasticity could theoretically address some of these overlapping mechanisms.
The findings may be particularly relevant for clinicians treating older adults who have not responded adequately to standard antidepressants or who experience troublesome side effects.
Why Might ALC Affect Mood?
ALC appears to act through several pathways rather than a single neurotransmitter system.
Potential mechanisms include:
- Supporting mitochondrial energy production and fatty-acid transport
- Increasing brain-derived neurotrophic factor, or BDNF, which is involved in neuronal growth and adaptability
- Modulating glutamatergic signaling, including mGlu2 receptor activity
- Influencing serotonin and dopamine pathways
- Reducing aspects of neuroinflammation
- Supporting synaptic plasticity in mood-related brain circuits
This multimodal activity is one reason ALC has attracted attention as a possible alternative or add-on treatment. It may influence the biological systems that help the brain adapt to stress and recover from prolonged depressive states.
However, many of these mechanisms are based on preclinical or early-stage research. A plausible mechanism does not guarantee clinical effectiveness, and more research is needed to determine which patients are most likely to benefit.
→ Discover more content related to brain and mental health in our Mood Support Resource Center.
What About Bipolar Depression?
The evidence for bipolar depression remains limited and less encouraging. One randomized trial examined ALC in combination with alpha-lipoic acid for bipolar depression and did not find a significant improvement compared with placebo.
The findings for major depressive disorder should not automatically be applied to bipolar disorder. Anyone with bipolar symptoms should work with a qualified clinician, particularly because treatments and supplements can affect mood stability and may carry risks in the context of mania or hypomania.
Safety and Clinical Implications
Across the included studies, ALC was generally well tolerated. Reported side effects were mainly mild gastrointestinal or central nervous system symptoms. Serious adverse events were rare and were not attributed to ALC in the studies that reported them.
Even so, the safety evidence has limitations. Four of the 15 studies did not report adverse-event data, and reporting methods differed between trials. The review also did not identify a clear relationship between dose, treatment duration and benefit. In other words, the available evidence cannot establish an optimal dose or tell clinicians how long treatment should continue.
The new review strengthens the case for studying ALC in depression, particularly among older adults and people with difficult-to-treat illness. Its effects appeared comparable to standard antidepressants in limited direct comparisons, and its tolerability profile was generally favorable.
The larger message is perhaps the most important one: depression treatment may increasingly move toward personalized care that considers brain energy metabolism, inflammation, age, cognition and treatment history—not neurotransmitters alone.
→ Download the Full Text here.
Reference
Kumar R, Hashempour Z, Shahriarirad S, Shahriarirad R, Hassett LC, Singh B, Croarkin PE, Veldic M, Frye MA, Pagali SR. Current Evidence of Acetyl-L-Carnitine Use in Mood Disorders-: A Systematic Review and Meta-Analysis. Neuropsychiatr Dis Treat. 2026 Jun 3;22:586506. doi: 10.2147/NDT.S586506. PMID: 42261369; PMCID: PMC13242760.
Acetyl-L-Carnitine and Depression: What a New Meta-Analysis Reveals
A recently published systematic review and meta-analysis suggests that acetyl-L-carnitine (ALC) may have a meaningful role to play for people with depression, especially treatment-resistant or late-life depression.
The findings do not establish ALC as a replacement for antidepressants or psychotherapy; however, they add to growing evidence that depression may involve more than neurotransmitter imbalance alone. Mitochondrial function, brain plasticity, inflammation and metabolic health may also influence who develops depression—and who responds to treatment.
ALC—Depression Biomarker and Treatment
Acetyl-L-carnitine, produced naturally in the body, helps transport fatty acids into mitochondria, structures that generate energy inside cells. Because the brain has high energy demands, disruptions in mitochondrial function may affect mood, cognition and resilience to stress.
ALC crosses the blood-brain barrier more efficiently than standard L-carnitine, which explains the compound’s increased attention in psychiatric research, where investigators are exploring its possible effects on neuroplasticity, neurotransmission and cellular energy production.
Previous research has suggested that people with major depressive disorder may have lower ALC levels than individuals without depression. Lower levels of ALC have also been associated with greater depression severity and longer illness duration. These observations raise an intriguing possibility—ALC may be both a potential biomarker and a treatment target.
What Did the New Study Examine?
Published in Neuropsychiatric Disease and Treatment (link to full text below), the review by Kumar and colleagues synthesized evidence from 15 clinical studies. Fourteen were randomized controlled trials and one was an open-label study. Together, the studies included 809 participants, although only 10 trials had sufficient data to be included in the main meta-analysis.
Participants received ALC either alone or alongside another treatment. The studies included people with major depressive disorder, dysthymic disorder and bipolar depression. Treatment periods ranged from approximately 40 days to 12 weeks, with reported ALC doses ranging from 1 to 3 grams per day.
The researchers compared changes in depressive symptoms using common clinical rating scales, including the Hamilton Depression Rating Scale, Beck Depression Inventory and Montgomery–Åsberg Depression Rating Scale.
Depressive Symptoms Improved More with ALC Overall
Across 10 randomized controlled trials involving 725 participants, the pooled results favored ALC over control conditions. The primary analysis found a statistically significant reduction in depressive symptoms, with a standardized mean difference of −1.20.
The strongest evidence appeared on the Hamilton Depression Rating Scale—in that analysis, ALC was associated with greater symptom improvement than the control treatment. Results using the Beck Depression Inventory and MADRS also favored ALC, although their confidence intervals included the possibility of no clear difference.
That distinction matters. The overall direction of results was encouraging, but the findings were not equally conclusive across every measurement tool.
The review also found that ALC performed similarly to standard antidepressant medications in the limited head-to-head studies available. In trials comparing ALC with amisulpride or fluoxetine, symptom improvement was broadly comparable. ALC appeared to be better tolerated in some of these comparisons, although the number of studies was small.
Older Adults May Be Especially Responsive
One of the most notable findings came from the age-based subgroup analysis. Trials involving adults aged 60 and older showed a larger apparent benefit than studies primarily enrolling younger adults.
In older-adult studies, the pooled standardized mean difference was −1.88, compared with −0.28 in studies involving younger participants. The researchers caution that this finding should be interpreted carefully because the number of trials in each subgroup was limited.
Still, the result is biologically plausible. Late-life depression may involve mitochondrial dysfunction, inflammation, vascular changes, cognitive impairment and neurodegenerative processes. A treatment that supports cellular energy metabolism and neuroplasticity could theoretically address some of these overlapping mechanisms.
The findings may be particularly relevant for clinicians treating older adults who have not responded adequately to standard antidepressants or who experience troublesome side effects.
Why Might ALC Affect Mood?
ALC appears to act through several pathways rather than a single neurotransmitter system.
Potential mechanisms include:
This multimodal activity is one reason ALC has attracted attention as a possible alternative or add-on treatment. It may influence the biological systems that help the brain adapt to stress and recover from prolonged depressive states.
However, many of these mechanisms are based on preclinical or early-stage research. A plausible mechanism does not guarantee clinical effectiveness, and more research is needed to determine which patients are most likely to benefit.
What About Bipolar Depression?
The evidence for bipolar depression remains limited and less encouraging. One randomized trial examined ALC in combination with alpha-lipoic acid for bipolar depression and did not find a significant improvement compared with placebo.
The findings for major depressive disorder should not automatically be applied to bipolar disorder. Anyone with bipolar symptoms should work with a qualified clinician, particularly because treatments and supplements can affect mood stability and may carry risks in the context of mania or hypomania.
Safety and Clinical Implications
Across the included studies, ALC was generally well tolerated. Reported side effects were mainly mild gastrointestinal or central nervous system symptoms. Serious adverse events were rare and were not attributed to ALC in the studies that reported them.
Even so, the safety evidence has limitations. Four of the 15 studies did not report adverse-event data, and reporting methods differed between trials. The review also did not identify a clear relationship between dose, treatment duration and benefit. In other words, the available evidence cannot establish an optimal dose or tell clinicians how long treatment should continue.
The new review strengthens the case for studying ALC in depression, particularly among older adults and people with difficult-to-treat illness. Its effects appeared comparable to standard antidepressants in limited direct comparisons, and its tolerability profile was generally favorable.
The larger message is perhaps the most important one: depression treatment may increasingly move toward personalized care that considers brain energy metabolism, inflammation, age, cognition and treatment history—not neurotransmitters alone.
→ Download the Full Text here.
Reference
Kumar R, Hashempour Z, Shahriarirad S, Shahriarirad R, Hassett LC, Singh B, Croarkin PE, Veldic M, Frye MA, Pagali SR. Current Evidence of Acetyl-L-Carnitine Use in Mood Disorders-: A Systematic Review and Meta-Analysis. Neuropsychiatr Dis Treat. 2026 Jun 3;22:586506. doi: 10.2147/NDT.S586506. PMID: 42261369; PMCID: PMC13242760.
Related Articles
60-Day Mind|Set Challenge Shows Anxiety Improvements
Read MoreThe Endocannabinoid–Adrenal Connection Behind Seasonal Immune Challenges
Read MoreEssential Oils as Multitarget Therapeutics: A Microbiome-Centered, Evidence-Informed Approach to Clinical Practice
Read More